WallStreetZenWallStreetZen

NYSEMKT: OCX
ONCOCYTE CORP Earnings & Revenue

OCX past revenue growth

How has OCX's revenue growth performed historically?
Company
245.25%
Industry
1,038.99%
Market
49.97%
OCX's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
OCX's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Market Performance
OCX's revenue growth is accelerating... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

OCX earnings and revenue history

Current Revenue
$8.0M
Current Earnings
-$70.5M
Current Profit Margin
-877.9%

OCX Return on Equity

Current Company
-86.9%
Current Industry
7.7%
Current Market
38.4%
OCX's Return on Equity (-86.9%)... subscribe to Premium to read more.
High Return on Equity Performance

OCX Return on Assets

Current Company
-43.3%
Current Industry
5.5%
OCX is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

OCX Return on Capital Employed

Current Company
-54.41%
Current Industry
-16.4%
OCX's ability to generate Return... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

OCX vs Biotech Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
OCX$8.03M-$67.03M-$70.47M+2,139.84%N/A
GMDA$0.00-$89.61M-$91.98MN/AN/A
IKNA$30.90M-$39.39M-$41.24M+227.25%N/A
AMTI$0.00-$112.98M-$122.40MN/AN/A
OBSV$0.00-$42.84M-$50.17MN/AN/A

ONCOCYTE Earnings & Revenue FAQ

What were OCX's earnings last quarter?

On Invalid Date, ONCOCYTE (NYSEMKT: OCX) reported Q1 2022 earnings per share (EPS) of -$0.11, up 120% year over year. Total ONCOCYTE earnings for the quarter were -$10.29 million. In the same quarter last year, ONCOCYTE's earnings per share (EPS) was -$0.05.

What was OCX's earnings growth in the past year?

As of Q2 2022, ONCOCYTE's earnings has grown null year over year. ONCOCYTE's earnings in the past year totalled -$70.47 million.

What was OCX's revenue last quarter?

On Invalid Date, ONCOCYTE (NYSEMKT: OCX) reported Q1 2022 revenue of $1.42 million up 26.69% year over year. In the same quarter last year, ONCOCYTE's revenue was $1.12 million.

What was OCX's revenue growth in the past year?

As of Q2 2022, ONCOCYTE's revenue has grown 245.25% year over year. This is 793.75 percentage points lower than the US Biotechnology industry revenue growth rate of 1,038.99%. ONCOCYTE's revenue in the past year totalled $8.03 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.